{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is predicted to function as a stress-responsive protein scaffold mediating the regulation of mitogen activating protein kinase (MAPK) pathways, and mutations such as Y1699C result in a loss of protection against oxidative stress, making cells more vulnerable.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a loss of protective function against oxidative stress due to impaired activation of the ERK pathway in LRRK2 mutants, which is relevant to parkinsonian symptoms."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses cell viability assays (WST-1, LDH, direct cell count) and immunoblotting to assess ERK pathway activation in response to H2O2-induced oxidative stress in HEK293 and SH-SY5Y cells.",
          "judgment": "Yes",
          "reasoning": "Cell viability and signaling pathway activation assays are relevant and widely used in the field to model the impact of LRRK2 mutations on cellular stress responses, reflecting the disease mechanism of Parkinson's disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 and empty vector (pCDNA3.1) were used as controls; experiments were performed with at least 2-3 independent experiments and 6-8 replicates per condition for HEK293 cells, and 3 readings from independent experiments for SH-SY5Y cells.",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type LRRK2) and negative (empty vector) controls are included, and the paper explicitly mentions multiple independent experiments with replicates, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study includes G2019S, another known pathogenic LRRK2 mutation, as a comparator alongside Y1699C, with functional outcomes compared to wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variant G2019S is used as a control, meeting the criteria for variant controls in the assay.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance was assessed using ANOVA and post hoc Fisher's PLSD tests with p<0.05 considered significant; data are reported as means ± SEM with multiple readings per data point.",
          "judgment": "No",
          "reasoning": "While statistical tests are performed, there is no direct calculation or estimation of OddsPath or equivalent quantitative measure of pathogenicity likelihood for the functional data specific to Y1699C.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Only one additional variant control (G2019S) is explicitly tested alongside Y1699C in the functional assays.",
          "judgment": "10 or less",
          "reasoning": "The total number of benign/pathogenic variant controls used in the study is less than 11 (only G2019S is mentioned as a control variant), limiting the strength of evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 Y1699C supports a pathogenic role with a strength of PS3_supporting. This is based on the clear disease mechanism, appropriate assay types, presence of basic and variant controls, but limited by the lack of OddsPath calculation and fewer than 11 variant controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations such as G2019S result in a loss of protection against oxidative stress, making cells more vulnerable, likely due to impaired activation of the ERK pathway.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as a loss of protective function against oxidative stress due to impaired ERK pathway activation in LRRK2 mutants, relevant to parkinsonian symptoms."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses cell viability assays (WST-1, LDH, direct cell count) and immunoblotting to assess ERK pathway activation in response to H2O2-induced oxidative stress in HEK293 and SH-SY5Y cells.",
          "judgment": "Yes",
          "reasoning": "Cell viability and signaling pathway activation assays are relevant and widely used to model the impact of LRRK2 mutations on cellular stress responses, reflecting the disease mechanism of Parkinson's disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 and empty vector (pCDNA3.1) were used as controls; experiments were performed with at least 2-3 independent experiments and 6-8 replicates per condition for HEK293 cells, and 3 readings from independent experiments for SH-SY5Y cells.",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type LRRK2) and negative (empty vector) controls are included, and multiple independent experiments with replicates are mentioned, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study includes Y1699C, another known pathogenic LRRK2 mutation, as a comparator alongside G2019S, with functional outcomes compared to wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variant Y1699C is used as a control, meeting the criteria for variant controls in the assay.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance was assessed using ANOVA and post hoc Fisher's PLSD tests with p<0.05 considered significant; data are reported as means ± SEM with multiple readings per data point.",
          "judgment": "No",
          "reasoning": "While statistical tests are performed, there is no direct calculation or estimation of OddsPath or equivalent quantitative measure of pathogenicity likelihood for the functional data specific to G2019S.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Only one additional variant control (Y1699C) is explicitly tested alongside G2019S in the functional assays.",
          "judgment": "10 or less",
          "reasoning": "The total number of benign/pathogenic variant controls used in the study is less than 11 (only Y1699C is mentioned as a control variant), limiting the strength of evidence.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 G2019S supports a pathogenic role with a strength of PS3_supporting. This is based on the clear disease mechanism, appropriate assay types, presence of basic and variant controls, but limited by the lack of OddsPath calculation and fewer than 11 variant controls."
    }
  ]
}